The Government of Canada is giving $199.16 million to help Resilience Biotechnologies Inc. expand its vaccine production capacity.
The feds say this investment will support a $401.52-million project at the company’s Mississauga, Ont. factory. The federal cash comes from its Strategic Innovation Fund.
Resilience Biotechnologies is a subsidiary of San Diegeo, Calif.-based vaccine manufacturer National Resilience Inc. The government says there is currently no contract development and manufacturing organization (CDMO) in Canada able to produce sufficient vaccines for national and international demands. Resilience Biotechnologies Inc. is expected to meet these needs with this project.
“Today’s contribution to Resilience Biotechnologies Inc. is another important step to support Canada’s leadership in the life sciences sector and to build its pandemic preparedness. These investments are also creating well-paying jobs and helping to grow Canada’s life sciences ecosystem as an engine for our economic recovery,” says François-Philippe Champagne, Minister of Innovation, Science and Industry.
Resilience Biotechnologies Inc. says the project will increase its manufacturing and fill-finish capacity for a number of vaccines and therapeutics, including for those that use novel technology such as mRNA and that are now being deployed to fight COVID-19. The company’s Mississauga facility is expected to have the capacity to manufacture approximately 112 million to 640 million doses of mRNA vaccines per year. The company says the expansion will maintain 295 existing jobs and create 205 new full-time positions in Canada and create 50 co-op positions.
“Resilience is honoured to partner with the ISED Strategic Innovation Fund to expand our infrastructure, talent and overall capacity, allowing us to improve Canada’s pandemic preparedness and further strengthen the Canadian biopharmaceutical ecosystem,” says Rahul Singhvi, CEO of National Resilience, Inc.
The project will modernize existing space at the site (approximately 10,000 square feet) and building an extension to the site (approximately 45,000 square feet). In addition, this project will increase capacity to manufacture and fill-finish vaccines and therapeutics on a commercial scale, including mRNA vaccines and other biologics.
National Resilience Inc. is a manufacturing and technology company dedicated to broadening access to complex medicines and protecting biopharmaceutical supply chains against disruption.
Resilience Biotechnologies Inc. is a wholly owned subsidiary of National Resilience Inc. located in Mississauga, Ontario, specializing in the development and manufacture of clinical and commercial complex biologics, vaccines and aseptic fill-finish as a contract development and manufacturing organization (CDMO).
“Resilience was founded during the pandemic to build a better system for manufacturing complex medicines to fight deadly diseases,” says Singhvi. “This partnership with the Government of Canada will help prepare Canada for future pandemics and strengthen the country’s biopharmaceutical ecosystem.”